Form 4: Elevance Health Director Steven Collis Receives Stock Units

Director Steven H. Collis acquired 563 deferred stock units as part of the Elevance Health, Inc. Board of Directors Compensation Program.

Summary

• Director Steven H. Collis was granted 563 deferred stock units on May 13, 2026.
• The grant was issued under the Elevance Health, Inc. Board of Directors Compensation Program.
• Following this transaction, the reporting person holds a total of 4,202 shares of common stock directly.
• The units are payable in common stock upon the earlier of five years from the grant date or the director's departure from the board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The deferred stock units are scheduled to vest and become payable in common stock in five years or upon the director's departure from the board, whichever occurs first.

Industry Context

StockSavvy.ai notes that equity-based compensation for board members is a standard corporate governance practice in the healthcare sector to ensure long-term alignment with company performance.

Comparison to Industry Standards

• The use of deferred stock units for board compensation is consistent with standard practices among large-cap healthcare companies like UnitedHealth Group and Cigna.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation disclosure.

Next Steps

• The reporting person will hold the deferred stock units until the earlier of five years or their departure from the board.

Key Dates

Keywords

Elevance Health, ELV, Form 4, Insider Trading, Director Compensation, Steven Collis